Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials
复制标题
DOI：
10.1007/s10461-020-02918-x
复制
发表时间：
2020-05-14
影响因子：
4.4
通讯作者：
Kerrigan, Deanna
中科院分区：
文献类型：
--
作者：
Mantsios, Andrea;Murray, Miranda;Kerrigan, Deanna
长效注射抗逆转录病毒疗法(LA ART)可能是有依从性挑战或不愿服药的艾滋病毒携带者(PLHIV)的替代方案。通过深入访谈，本研究试图了解PLHIV(n=53)在美国和西班牙参加洛杉矶ART试验第三阶段的经历。在考虑LA ART时，最突出的考虑是它的临床疗效；许多参与者报告说，希望确保它与日常口腔ART一样有效，包括减少剂量(每8周对4周)。虽然注射副作用经常被报道，但大多数参与者认为方案的好处超过了这些缺点。参与者将洛杉矶抗逆转录病毒疗法的主要好处描述为它在后勤和心理上提供的“自由”，包括通过减少艾滋病毒的污名。研究结果强调了与权衡潜在益处和副作用相关的患者-提供者沟通的重要性，以及继续需要解决艾滋病毒污名问题。
Long-acting injectable antiretroviral therapy (LA ART) may be an alternative for people living with HIV (PLHIV) with adherence challenges or who prefer not to take pills. Using in-depth interviews, this study sought to understand the experiences of PLHIV (n = 53) participating in Phase 3 LA ART trials in the United States and Spain. The most salient consideration when contemplating LA ART was its clinical efficacy; many participants reported wanting to ensure that it worked as well as daily oral ART, including with less frequent dosing (every 8 versus 4 weeks). While injection side effects were often reported, most participants felt that regimen benefits outweighed such drawbacks. Participants described the main benefit of LA ART as the "freedom" it afforded both logistically and psychosocially, including through reduced HIV stigma. Findings highlight the importance of patient-provider communication related to weighing potential benefits and side effects and the continued need to address HIV stigma.